Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | AGXT | P21549 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 9/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9347048 | 0.88 | IDO1 (0.64) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL1310466 | 0.86 | TSHR (0.42) | IDO1AGXT | |
| SCHEMBL8132483 | 0.85 | IDO1 (0.60) | IDO1AGXTMAOBCYP1A2CYP2D6 | |
| SCHEMBL30487709 | 0.85 | IDO1 (0.60) | IDO1AGXTMAOBCYP1A2CYP2D6 | |
| SCHEMBL1767187 | 0.84 | IDO1 (0.69) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL27037812 | 0.84 | IDO1 (0.55) | IDO1AGXTMAOBCYP1A2CYP2D6 | |
| SCHEMBL613278 | 0.81 | IDO1 (0.56) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL3456515 | 0.81 | IDO1 (0.56) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL30449898 | 0.81 | IDO1 (0.51) | IDO1AGXTMAOBTAAR1MAOA | |
| SCHEMBL30932467 | 0.80 | IDO1 (0.48) | IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0979824-B1 | Process for the preparation of substituted piperidine-epoxides | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | claimed |
| WO-2000063173-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PIPERIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-26 | — | — | WO | claimed |
| EP-0979824-A1 | Process for the preparation of substituted piperidine-epoxides | F. HOFFMANN-LA ROCHE AG (CH) | 2000-02-16 | — | — | EP | claimed |
| US-9452153-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9056849-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-20140323530-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8716529-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8450527-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450527-B2 | Amine derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2012-02-16 | — | — | US | disclosed |
| EP-0979824-B1 | Process for the preparation of substituted piperidine-epoxides | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | disclosed |
| US-6268499-B1 | USEFUL AS RENIN INHIBITORS | HOFFMAN-LA ROCHE INC. | 2001-07-31 | — | — | US | disclosed |
| EP-1083919-A1 | NOVEL ANTIVIRAL COMPOUNDS | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-2000063173-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PIPERIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-26 | — | — | WO | disclosed |
| WO-1999064047-A9 | NOVEL ANTIVIRAL COMPOUNDS | ADVANCED MEDICINE INC (US) | 2000-03-16 | — | — | WO | disclosed |
| EP-0979824-A1 | Process for the preparation of substituted piperidine-epoxides | F. HOFFMANN-LA ROCHE AG (CH) | 2000-02-16 | — | — | EP | disclosed |
| WO-1999064047-A1 | NOVEL ANTIVIRAL COMPOUNDS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| EP-0863875-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997009311-A1 | NEW 4-(OXYALKOXYPHENYL)-3-OXY-PIPERIDINES FOR TREATING HEART AND KIDNEY INSUFFICIENCY | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041039-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | IDO1 505/4885AGXT 1594/4885MAOB 15/4885 |
| US-20140323530-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | IDO1 505/4885AGXT 1594/4885MAOB 15/4885 |
| US-20120041038-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, CLN6, AADAT | IDO1 505/4885AGXT 1594/4885MAOB 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.